About Us
TScan is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer.
TScan was founded in early 2018 to discover and develop TCR-T therapies using a novel target discovery platform.
Driven by our commitment to deliver life-changing therapies for patients with significant unmet medical needs, we used our proprietary discovery technology to understand how T cells naturally recognize and fight cancer and have leveraged this information to build a broad pipeline of TCR-T therapy candidates. Our technology has also allowed us to understand how T cells cause or contribute to autoimmune diseases, and we are actively discovering novel autoantigens for targeted therapeutics.
Our focus
We are striving to become a leader in developing in vivo-engineered TCR-T therapy for the treatment of solid tumor indications. We have identified two lead candidates, one targeting PRAME and the other targeting MAGE-A4, to advance into IND-enabling studies. Our approach is supported by our belief that an in vivo engineering approach will overcome the key limitations of ex vivo-engineered autologous TCR-T, including the cost and difficulty of patient-specific manufacturing, the delay in getting product to patients, and the need for lymphodepletion. We expect to share preclinical data in Q1 2027 and file our first IND in Q3 2027. Our plan is to initiate Phase 1 development in Q4 2027.
Our mission
Create and develop life-changing T-cell therapies for patients with cancer
Our Values
We are dedicated to creating and developing life-changing T-cell therapies for patients by engineering immunity